NFKB1 and esophageal cancer: Izzo et al(10) reported that activated NF-κB prior to therapy in 80 patients with esophageal cancer was associated with the lack of a complete pathological response, which supports the present result showing that patients with high expression levels of NF-κB had significantly poorer OS and DFS rates than those showing low levels.